Slimirex - Natural Weightloss Supplement

Pre Clinical Trial 3

Author: Dr. Edward Group 05/26/2009

Gugulipid Pre-Clinical Trial Research Three

Study 5

Objective: To study the lipid lowering activity of gugulipid in various animal models.

Normal rats: The different oral doses of gugulipid with or without other hypolipidemic agents were administered to normal rats. Some rats received 100 mg/kg body weight of gugulipid for 90 days. Another group received doses of gugulipid and/or clofibrate for 30 days. (fig 10 & 11)

Triton-treated rats: Hyperlipidemic rats were given 200 mg/kg body weight of gugulipid, 200 mg/kg body weight of clofibrate, or 1000mg/kg body weight of nicotinic acid. (fig 12)

Dietery cholesterol -induced hyperlipidemic rats: Hyperlipidemic rats fed a high cholesterol diet received gugulipid for a period of 14 days.

Ethanol-induced hyperlipidemic rats: Gugulipid 200 mg/kg and clofibrate 200 mg/kg were administered to the rats.

Rabbits: Hyperlipidemic rabbits (serum cholesterol levels > 500 mg/dl) received gugulipid 50 mg/kg body weight for eight weeks.

Monkeys: Normal rhesus monkeys were given gugulipid doses of 60 and 120 mg/kg body weight for 90 days.


Figure 10

Effect of gugulipid on the percentage of cholesterol lowering in normal rats (p<0.01).Serum triglycerides were also reduced by 30% (p < 0.05).

Figure 10

Figure 11

Effect of gugulipid and clofibrate on the reduction of serum lipids in normal rats (G = gugulipid and C = clofibrate).

Figure 11

Figure 12

Effect of gugulipid, clofibrate, and nicotinic acid on the reduction of serum lipids in triton-treated rats (G = guggulipid, C = clofibrate, N = nicotinic acid).

Figure 12

Gugulipid lowered serum cholesterol and triglyceride levels by 60.5% and 37.7% at day 14 in diet-induced hyperlipidemic rats.

Significant reductions in serum cholesterol and triglycerides (p<0.01) were observed in ethanol-induced hyperlipidemic rats given 200 mg/kg gugulipid. These reductions were 30% more than clofibrate at the same dose.

Administration of 50 mg/kg gugulipid produced significant reductions of 40% in serum cholesterol and 30% in triglycerides in hyperlipidemic rabbits.

Levels of serum cholesterol, triglycerides, LDL, and VLDL were lowered by 20-30%, 15-30%, 50%, and 30%, respectively in gugulipid-treated, normal rhesus monkeys.

Conclusions: Gugulipid was effective in reducing serum lipid levels in rats, rabbits, and monkeys. Its effects were comparable or better than the conventional hypolipidemic agents in some cases.

Study 6

Objective: To study the effect of gugulipid on atheroma formation and regression in hyperlipidemic animal models.

Results: Gugulipid inhibited elevated levels of serum cholesterol and triglycerides (p<0.001) in hyperlipidemic rabbits in 90 days. In addition, it raised HDL and apoproteins by 29% and 21%, respectively. A marked reduction of 50% in atheroma was observed in treated rabbits compared to a 60% increase in atheromatic lesions in untreated rabbits.

Significant reductions in serum cholesterol (p<0.01) and triglycerides (p<0.05) were observed in hyperlipidemic rhesus monkeys that received gugulipid. A regression in atheromatous lesions was also observed.

Conclusions: Gugulipid lowered serum lipids and reduced the formation of atheromatous lesions.

Study 7

Objective: To investigate the effects of C. mukul on melatonin-induced hypothyroidism in mice.

Methods: One hundred and eight mice were divided into three groups:

  1. A dose of 25 mg/100 g body weight of melatonin was administered to the rats intraperitoneally for 8 days. Subgroups were created from Group I. Subgroup 1 received 20 mg/ 100g body weight of C. mukul extract i.p., and subgroup 2 served as controls.
  2. A dose of melatonin (25 mg/100 g body weight) combined with C. mukul (20 mg/100 g body weight) i.p.
  3. This group served as normal controls. They only received saline solution.

The thyroid function of the animals was studied by assessing the structural and functional status of the thyroid gland.


The melatonin-treated group showed significant reductions in thyroid weight and secretions. In contrast, increased thyroid secretions, iodine uptake, and thyroid weights were observed in mice treated with C. mukul extract. A reversal of the symptoms induced by melatonin-induced hypothyroidism were reversed by the combined treatment of melatonin and C. mukul extract. Histological studies revealed that the combined C. mukul extract/melatonin treatment brought about increased follicular cell height compared to the reduced cell height of the mice treated solely with melatonin.

Conclusions: C. mukul stimulates thyroid function and helps to normalize the thyroid lowering activity of melatonin.

Study 8

Objective: To investigate the thyroid stimulating effects of Z-guggulsterone in rats.

Methods: Albino rats received doses of 1 mg/100 g body weight of Z-guggulsterone orally. The animals were sacrificed after specified periods and various biochemical parameters (peroxidase and protease activities of the thyroid and iodine uptake) were measured to determine changes in thyroid activity.

Figure 13

Effect of Z-guggulsterone on thyroid peroxidase activity (measured as in terms of moles o-dianisidine oxidized/minute/mg/tissue).

Figure 13

Figure 14

Effect of Z-guggulsterone on thyroid proteolytic activity (measured in terms of µg tyrosine liberated /mg thyroid tissue). (n=6)

Figure 14

Figure 15

Effect of Z-guggulsterone on the iodine concentration ratio (measured in terms of counts/g thyroid tissue divided by counts/ml serum). (n=6)

Figure 15

Conclusions: Z-guggulsterone stimulated thyroid activity in rats as evidenced by the significant increases in thyroid function parameters. (n=6)
Posted In: Gugulipid

The Ultimate Weight Loss Formula

The world's most advanced weight loss supplement

Slimirex® is the only advanced weight management formula in the world combining 10 proven fat-fighting and appetite suppressing nutrients in every dose.

Only $49.95

FREE shipping and returns

 or  All orders ship for Free!*

Call Us Today
Slimirex® Weigh Loss Quick Help GHC on the Web
Follow us on the web: Google +1 Profile GHC on Youtube  GHC on Facebook  GHC on Twitter
Global Healing Center | 2040 North Loop West, Ste. 108 | Houston, Texas 77018
Telephone: 713-476-0016 | Toll Free: 1-800-476-0016 | Fax: 713-476-0017

DISCLAIMER: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Information and statements made are for education purposes and are not intended to replace the advice of your treating doctor. Global Healing Center does not dispense medical advice, prescribe, or diagnose illness. We design and recommend individual nutritional programs and supplements that allow the body to rebuild and heal itself. The views and nutritional advice expressed by Global Healing Center are not intended to be a substitute for conventional medical service. If you have a severe medical condition, see your physician of choice. This Web site contains links to Web sites operated by other parties. Such links are provided for your convenience and reference only. We are not responsible for the content or products of any linked site or any link contained in a linked site.

© Copyright 1998 - 2019 | All Rights Reserved